logo

Cti Biopharma Corp. (CTIC)



Trade CTIC now with
  Date
  Headline
8/2/2018 8:04:24 AM CTI BioPharma Q2 Net Loss $11.3 Mln Or $0.20 Per Share
7/18/2018 7:01:31 AM CTI BioPharma Says It Recently Conducted A Type B Meeting With FDA For Its Lead Product Candidate Pacritinib
7/9/2018 7:01:40 AM CTI BioPharma: PIXUVRI Plus Rituximab Did Not Show Statistically Significant Improvement In Progression-free Survival
7/2/2018 7:02:12 AM CTI BioPharma Announces The Continuation Without Modification Of PAC203 Phase 2 Study Of Pacritinib
5/3/2018 4:04:05 PM CTI BioPharma Q1 Loss Per Share $0.08 Vs Loss $0.71 Last Year
3/9/2018 7:01:38 AM CTI BioPharma Announces Publication Of Pacritinib Phase 3 PERSIST-2 Clinical Trial In JAMA Oncology
3/7/2018 4:02:53 PM CTI BioPharma Q4 Net Loss $14.3 Mln Or $0.33 Per Share Vs Net Loss $6.4 Mln Or $0.23 Per Share Last Year
2/13/2018 7:02:04 AM CTI BioPharma Says Closes Underwritten Public Offering Of 20 Mln Shares At $3.00/shr
2/9/2018 7:01:50 AM CTI BioPharma Prices Public Offering Of 20 Mln Shares Of Common Stock
2/5/2018 7:56:02 AM CTI BioPharma Launches Proposed Public Offering Of Shares